Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Insmed ( (INSM) ) has shared an update.
On June 11, 2025, Insmed announced the commencement and pricing of a public offering of its common stock, aiming to raise $650 million, with an option for underwriters to purchase additional shares. The offering, managed by Goldman Sachs and Leerink Partners, is expected to generate approximately $716.3 million in net proceeds, potentially impacting Insmed’s financial position and market operations.
The most recent analyst rating on (INSM) stock is a Buy with a $72.00 price target. To see the full list of analyst forecasts on Insmed stock, see the INSM Stock Forecast page.
Spark’s Take on INSM Stock
According to Spark, TipRanks’ AI Analyst, INSM is a Neutral.
The most significant factor affecting Insmed’s stock score is its financial performance, characterized by consistent losses and high leverage. Technical analysis offers a mixed outlook, with some bullish momentum but overbought conditions. Valuation remains unattractive due to negative earnings. However, recent corporate events, such as successful clinical trial results and shareholder backing, provide positive momentum.
To see Spark’s full report on INSM stock, click here.
More about Insmed
Insmed Incorporated is a global biopharmaceutical company focused on delivering innovative therapies for serious diseases. The company is advancing a diverse portfolio of approved and investigational medicines, particularly in pulmonary and inflammatory conditions, and utilizes cutting-edge technologies such as gene therapy and AI-driven protein engineering.
Average Trading Volume: 2,783,060
Technical Sentiment Signal: Buy
Current Market Cap: $17.85B
For detailed information about INSM stock, go to TipRanks’ Stock Analysis page.